


BMJ Open Prospective evaluation of an ultrathin strut biodegradable polymer-coated sirolimus-eluting stent: 12 months' results from the S-FLEX UK registry

Anirban Choudhury,¹ Scot Garg,² Jamie Smith,³ Andrew Sharp,⁴ Sergio Nabais de Araujo,⁵ Anoop Chauhan,⁶ Nikhil Patel,⁷ Benjamin Wrigley,⁸ Sudipta Chattopadhyay ,⁹ Azfar G Zaman¹⁰

To cite: Choudhury A, Garg S, Smith J, *et al.* Prospective evaluation of an ultrathin strut biodegradable polymer-coated sirolimus-eluting stent: 12 months' results from the S-FLEX UK registry. *BMJ Open* 2019;**9**:e026578. doi:10.1136/bmjopen-2018-026578

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2018-026578>).

Received 16 September 2018
Revised 01 September 2019
Accepted 03 September 2019

ABSTRACT

Objective To prospectively evaluate safety and efficacy of the ultrathin strut biodegradable polymer-coated Supraflex sirolimus-eluting stent (S-SES) in 'real world' patient population requiring percutaneous coronary intervention (PCI).

Methods National, prospective, multicentre, single-arm, all-comers, observational registry of 469 patients treated with S-SES from July 2015 and November 2016 in 11 centres in UK. Primary endpoint was target lesion failure (TLF) at 12 months (cardiac death, target vessel myocardial infarction (MI) or clinically driven target lesion revascularisation (TLR)). Secondary endpoints included safety and performance outcomes at 12 months—overall stent thrombosis (ST), all-cause mortality, any MI, target vessel failure (TVF) and major adverse cardiac events (MACE—composite of cardiac death, MI, emergent or repeat revascularisation).

Results At 12 months, the primary endpoint occurred in 11 (2.4%) of 466 patients, consisting of 4 (0.9%) cardiac deaths, 3 (0.6%) target vessel MI and 7 (1.5%) TLR. Secondary endpoints findings included all-cause mortality in 6 (1.3%), TVF of 14 (3%), no definite ST, 1 (0.2%) probable ST and 3 (0.6%) possible ST. Overall MACE was observed in 18 (3.9%).

Conclusions The S-FLEX UK registry showed that the S-SES is safe with a low incidence of TLF in routine clinical practise in patients with coronary artery disease being treated by PCI.

INTRODUCTION

Drug-eluting stents (DES) reduce neointimal proliferation and restenosis compared with bare-metal stents.^{1 2} However, the persistence of adverse events with both first-generation and contemporary permanent polymer-based DES presents an opportunity for iterative improvement.^{3–5} These include development of new metal alloys with thin struts, improved stent design and development of bioresorbable polymers.^{6–10}

The potential link between durable polymer and late adverse events prompted

Strengths and limitations of this study

- The S-FLEX UK registry provides reassuring evidence that the ultrathin strut biodegradable polymer-coated sirolimus-eluting Supraflex stent can be safely and effectively used in routine clinical practice in UK patients with coronary artery disease being treated by percutaneous coronary intervention (PCI).
- The findings add to the emerging evidence that ultrathin strut biodegradable polymer stents can be used safely for PCI in routine clinical practice with the potential of further reducing target lesion failure.
- This is a non-randomised observational study of relatively small patient population with the inherent limitations of such studies. Nevertheless, the findings are consistent with other studies using the same product.
- The follow-up period was 12 months, and a longer period of follow-up would allow for more accurate assessment of very late stent thrombosis.

development of biodegradable polymers to reduce inflammatory response, facilitating re-endothelialisation and minimising risk of thrombus formation and late restenosis.^{11 12} Furthermore, first-generation DES with thick-strut design, are associated with more thrombotic events in ex vivo and experimental models.^{13 14} Newer DES technologies, with progressively thinner stent struts and biodegradable polymers promise additional benefit in terms of earlier re-endothelialisation and reduced restenosis.^{15 16}

In this multicentre UK registry, the objective was to assess safety and outcomes at 12 months of the CE-approved Supraflex (Saha-Janand Medical Technologies (SMT) Pvt Ltd, Surat, India), a biodegradable polymer-coated SES, ultrathin (60 µm) cobalt-chromium (Co-Cr) stent for the treatment of coronary artery disease (CAD) treated in routine clinical practice.



© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Azfar G Zaman;
azfar.zaman@nuth.nhs.uk

METHODS

Study design and patient population

The S-FLEX UK registry was a prospective, observational, multicentre, postmarketing registry designed to evaluate the safety and efficacy of the Supraflex sirolimus-eluting stent (S-SES) in a 'real-world' patient population. The study enrolled 469 patients from July 2015 until November 2016 in 11 centres in UK. All patients over the age of 18, undergoing percutaneous coronary intervention (PCI) with at least one study stent, according to guidelines for revascularisation, irrespective of indication, disease location or complexity, were eligible for enrolment. In keeping with its real-world design, exclusion criteria were minimal and included patients with a high-probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons); females of childbearing age; those with planned surgery within 6 months of PCI unless dual antiplatelet therapy (DAPT) could be maintained throughout the peri-surgical period; those participating in another study that has not completed the primary endpoint or that clinically interfered with the current registry requirements and those with a known intolerance to aspirin, any P2Y₁₂ drug, heparin, bivalirudin, cobalt, chromium, sirolimus or any other analogue or derivative, or contrast media. The registry, design and procedures complied with the principles of good clinical practice and the Declaration of Helsinki and were approved by the local ethics committee of each participating institution.

Patient and public involvement: All patients provided informed consent for the procedure and subsequent data collection and analysis for the research purposes. Patient and public were not involved in the designing of the registry, recruitment or conducting the registry.

Device description

The S-SES is a balloon-expandable stent using a medical grade cobalt-chromium alloy with ultra-thin struts of 60 µm and crowns which are linked together by flexible 'S' links to provide flexibility and improved deliverability. The coating layer, applied on the conformal surface of the stent with a mean thickness of 4–5 µm, comprises sirolimus, at a concentration of 1.4 µg/mm², blended together with biodegradable polymeric matrix (poly L-lactide, 50/50 poly DL-lactide-co-glycolide and polyvinyl pyrrolidone). The polymer facilitates programmed release such that 70% of the drug is released within 7 days and the remaining released over 48 days. The polymers retain their properties for a limited period and then gradually degrade into biologically inert molecules and excreted via normal metabolic pathways over 9–12 months. In addition, the device has a top protective layer that protects from light and moisture preventing premature drug release (figure 1). The device is available in diameters of 2.0, 2.25, 2.5, 2.75, 3.0, 3.50, 4.0 and 4.5 mm and in lengths increasing in 4 mm intervals from 8 to 48 mm. Across the range, the strut thickness is 60 µm.




Figure 1 Bio-degradable polymer matrix of Supraflex sirolimus-eluting stent. Drug dose: 1.4 µg/mm². Unique biodegradable polymer matrix: poly L-lactide, 50/50 poly DL-lactide-co-glycolide and polyvinyl pyrrolidone. Total coating thickness of 4–5 µm.

Study procedure

Standard interventional techniques were used to treat the lesion, with predilatation and postdilatation, procedural anticoagulation, use of glycoprotein IIb/IIIa inhibitors and duration of DAPT left to the operator's discretion.

Data collection and follow-up

Patient demographic data, lesion characteristics, procedure details and antithrombotic regimens were collected from each centre as per the prespecified case report form.

Follow-up was obtained at 12 months (±30 days) after the index procedure by hospital visit (14%) or telephonic follow-up. During follow-up consultations, information about patients' clinical condition, adverse events, hospitalisations and changes to concomitant (cardiac and antiplatelet) drugs were collected. Details of the above were further corroborated with review of the patients' electronic records and/or contacting the general practitioner.

Angiographic data were recorded for patients readmitted with ischaemia. For patients readmitted for ischaemia who underwent angiographic re-examination within 1 year, image analysis was performed to determine whether disease progression had occurred at the previously stented segment, including peri-stent areas 2 mm adjacent to the stent, or was limited to arterial segments remote from the stented region. If repeat angiography was performed <30 days after successful stent placement during the index procedure and demonstrated a significant stenosis or subacute stent thrombosis (ST) in the target vessel, the subject was considered an acute failure. If angiography took place ≥30 days after the index procedure and demonstrated restenosis of the target vessel and/or target lesion in association with objective evidence of recurrent ischaemia, the angiogram was analysed according to the secondary endpoints.

All events were investigator reported at site with no independent clinical events committee; however, site monitoring was performed to ensure continued protocol compliance and accurate data reporting by Psephos Biomedica (Sussex Innovation Centre, University of Sussex, Brighton BN1 9SB, UK).

Study endpoints

The primary endpoint of the study was target lesion failure (TLF) at 12 months: a composite of cardiac death, target vessel myocardial infarction (MI) or clinically driven target lesion revascularisation (TLR) by percutaneous

or surgical methods. Secondary endpoints assessed at 12 months included: overall ST; any death; any MI; any repeat revascularisation; target vessel failure (TVF) (a composite of cardiac death, target vessel MI or clinically driven TVR) and major adverse cardiac events (MACE—a composite of cardiac death, any MI, emergent or repeat revascularisation).

Statistical analysis

The sample size of subjects was selected to be similar to the patient numbers enrolled in the S-CORE registry.¹⁷ Data are presented using descriptive statistical methods. Continuous variables are presented as mean±SD, whereas categorical variables are expressed as percentages. All data were processed using the SPSS V.15

RESULTS

Baseline, lesion and patient characteristics

The S-FLEX registry enrolled 469 patients from 11 centres in UK between the prespecified recruitment periods of July 2015 to November 2016. Three patients withdrew consent and 12 were lost to follow-up leaving 454 (97.4%) patients for 12 months' clinical follow-up.

Baseline patient, lesion and procedural characteristics are shown in tables 1 and 2. Consistent with the all-comers design and reflective of a high-risk population active smoking, presence of diabetes, medical history of MI and revascularisation was noted in a quarter while over half had hypertension and hyperlipidaemia. Not all participating centres had a primary angioplasty service thereby explaining the lower number of patients with ST-elevation myocardial infarction that were recruited. However, in line with contemporary UK practice, the main indication for revascularisation was acute coronary syndrome (59.7%).¹⁸ The mean number of lesions per patient was 1.23±0.5, with >10% of these lesions bifurcations or chronic total occlusions. The mean number of stents deployed per patient was 1.48±1.0, with average length of coronary artery stented was 32.99±24.70 mm. Overall device implantation success on the lesion was 98.6%.

Clinical outcomes

Patient outcomes at 30 day, 6 months and 12 months are shown in table 3. The rate of the primary endpoint of TLF was 2 (0.4%) and 8 (1.7%) at 30 days and 6 months, respectively. At 12 months, the components of TLF, cardiac death was observed in 4 (0.9%), target vessel MI in 3 (0.6%) and TLR in 7 (1.5%). Cumulative TLF-free survival, at 12 months' follow-up, determined by the Kaplan-Meier method, was 97.4% as shown in figure 2.

Secondary endpoints findings included all-cause mortality in 6 (1.3%) and TVF in 14 (3%). According to ARC definition, overall ST was observed in 4 (0.8%) including no definite ST, 1 (0.2%) probable ST and 3 (0.6%) possible ST. Overall MACE were observed in 18 (3.9%) patients.

Table 1 Baseline characteristics of the study population

n (%) unless stated	
Patient characteristics	
n=466	
Age, mean±SD (years)	64.8±10.4
Male	350 (75.1%)
Body mass index (kg/m ²)	28.9±6.1
Diabetes mellitus	113 (24.2%)
Insulin requiring	30 (6.2%)
Non-insulin requiring	83 (18.0%)
Hypertension	237 (50.9%)
Hypercholesterolemia	251 (53.9%)
Family history of CAD	226 (48.5%)
Current smoker	120 (25.8%)
Renal insufficiency	10 (2.1%)
Peripheral vascular disease	17 (3.6%)
Congestive heart failure	12 (2.6%)
Previous transient ischaemic attack	12 (2.6%)
Previous stroke	17 (3.6%)
Previous myocardial infarction	127 (27.3%)
Previous PCI	108 (23.2%)
Previous CABG	18 (3.9%)
Acute coronary syndromes	278 (59.7%)
Unstable angina	187 (40.2%)
Silent ischaemia	10 (2.1%)
NSTEMI	58 (12.5%)
STEMI	23 (4.9%)
Stable angina	188 (40.3%)
Lesion characteristics	
n=573 lesions	
Number of lesions per patient (mean±SD)*	1.23 (±0.5)
Target vessel	
Left main stem	7 (1.2%)
Left anterior descending	249 (43.5%)
Left circumflex	119 (20.8%)
Right coronary artery	197 (34.4%)
Saphenous vein graft	1 (0.2%)
Re-stenotic lesion	16 (2.8%)
Bifurcation	61 (10.6%)
Total occlusion	75 (13.1%)

CABG, coronary artery bypass grafting; CAD, coronary artery disease; NSTEMI, non ST elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.


DISCUSSION

This UK multicentre real-world registry of the thin strut, cobalt-chromium, biodegradable polymer S-SES demonstrated safety with a low incidence of TLF and ST at 12 months.

Table 2 Procedural characteristics**Mean±SD unless stated**

Procedural characteristics	n=691 stents
No. of stents per patient	1.48±1.0
No. of stents per lesion	1.21±0.5
Mean stent length	22.48±7.6
Mean stent diameter	3.01±0.4
Predilatation, n (%)	471 (82.2)
Postdilatation, n (%)	394 (68.8)
Total stent length per patient	32.99±24.70
Device success (%)	98.6

Concerns related to impaired healing and persistent inflammation associated with first-generation durable polymer DES, led to the development of improved polymers, metallic platform technologies and thinner struts.^{3–10 14} The change in stent platform from stainless steel (132–140 µm) to chromium alloys (81–91 µm), reduced both procedural and late target vessel MI by about 40%–80%.^{19–22} The BIOFLOW V study compared the ultrathin strut (60 µm) bioresorbable polymer

**Figure 2** Kaplan-Meier curve of target lesion failure.

sirolimus-eluting Orsiro stent with the thin strut (81 µm) durable polymer everolimus-eluting Xience stent and reported an approximate further 40% reduction in target vessel MI in favour of Orsiro.¹⁰ The Orsiro stent polymer degrades over a 2 year span and thus the observed outcome differences at 1 year between the Orsiro and Xience stents are possibly largely driven by the difference in strut thickness rather polymer durability. Pooled analysis of large multicentre randomised trials reported lower risk of TVR

Table 3 Hierarchical and non-hierarchical subject counts of adverse events through 12 months (intent-to-treat population)

n (%)	30 days	6 months	12 months
Hierarchical events			
TLF	2 (0.4)	8 (1.7)	11 (2.4)
Cardiac death	1 (0.2)	3 (0.6)	4 (0.9)
Target-vessel MI	1 (0.2)	3 (0.6)	3 (0.6)
Target-lesion revascularisation	0 (0)	5 (1.1)	7 (1.5)
Target vessel failure	2 (0.4)	11 (2.4)	14 (3.0)
Major adverse cardiovascular events	4 (0.9)	14 (3.0)	18 (3.9)
Non-hierarchical events			
Death	1 (0.2)	1 (0.2)	6 (1.3)
Cardiac death	1 (0.2)	3 (0.6)	4 (0.9)
Non-cardiac death	0 (0.0)	1 (0.2)	2 (0.4)
Myocardial infarction			
Target vessel	1 (0.2)	3 (0.6)	3 (0.6)
Non-target vessel	2 (0.4)	3 (0.6)	4 (0.9)
Revascularisation			
Target lesion revascularisation	1 (0.2)	5 (1.1)	7 (1.5)
Target vessel revascularisation	1 (0.2)	10 (2.2)	14 (3.0)
Non target vessel revascularisation	2 (0.4)	4 (0.8)	6 (1.2)
Stent thrombosis	1 (0.2)	3 (0.6)	4 (0.9)
Definite ST	0 (0.0)	0 (0.0)	0 (0.0)
Probable ST	1 (0.2)	1 (0.2)	1 (0.2)
Possible ST	0 (0.0)	2 (0.4)	3 (0.6)

MACE, major adverse cardiac events (composite of cardiac death, any MI, emergent or repeat revascularisation); MI, myocardial infarction; ST, stent thrombosis; TLF, target lesion failure (composite of cardiac death, target vessel MI or clinically driven TLR); TVF, target vessel failure (composite of cardiac death, target vessel MI and TVR); TVR, target vessel revascularisation.

and very late ST associated with biodegradable polymers compared with durable polymer-coated DES.²³ However, it remains debatable whether this reduction of adverse events is a class effect of biodegradable polymers and may well be influenced by additional factors including stent strut thickness, polymer composition, distribution and load.^{24 25}

Studies assessing the Supralimus-Core (previous version of the S-SES with the same strut thickness, polymer and drug concentration) reported reassuring vessel healing properties by optical coherence tomography at 4 months,²⁶ along with satisfactory 1-year TLR of 1.1% along with MACE of 3.4% in real-world patients.¹⁷

The S-SES is an improved version of the Supralimus-Core SES with replacement of the rigid interlink/joint of the Supralimus-Core SES with a highly flexible 'S-link', which increases flexibility and deliverability. Preliminary evaluation of clinical and angiographic outcomes of the Supraflex stent in the MANIPAL-FLEX Study reported a TLR of 2.1%.²⁷ Angiographic in-stent late lumen loss, a dependable predictor of the long-term clinical efficacy of DES,²⁸ was observed to be 0.18 ± 0.23 mm with the Supraflex stent at 9 months in keeping with currently used effective DES systems.^{29–31}

The subsequent retrospective, multicentre FLEX registry that included 995 unselected patients treated with the S-SES across nine centres in India reported a 12-month MACE of 3.7%.³² This included TLR of 0.7%, definitive ST of 0.3% and overall ST of 1.1% at 12 months. Late ST remains a major concern even in contemporary DES and has been shown to be dependent on lack of strut coverage.³³ In the FLEX registry OCT subgroup analysis, the authors reported 98.1% strut coverage at 6 months with the S-SES, that compared favourably with the 91.5% and 94.1% strut coverage reported with Promus Element and Xience DES.³⁴ The authors also reported S-SES to have an excellent healing index of 4.8 (1.0–22.9) comparing favourably with BioMatrix (35.2 ± 25.0),

Cypher (43.3 ± 36.2), Resolute (18.7 ± 20.4) and the Xience (10.8 ± 15.3) DES systems.^{35 36}

In this registry, 12-month TLF of 2.4% and TLR of 1.5% is in keeping with the previous findings of the S-SES in the MANIPAL-FLEX and FLEX registries. These findings are encouraging when compared with the 12-month TLR and TLF of contemporary DES systems (figure 3).^{10 22 37–40}

The promising clinical outcomes with the S-SES might be attributed to the combination of its ultrathin struts, biodegradable polymer and unique platform design. Extensive strut coverage within 4–6 months and low 'healing index' provide possible explanations for low ST and TLR rates.⁴¹ The relative safety and efficacy of the S-SES seen in this registry was confirmed by the TALENT (Thin strut sirolimus-eluting stent in *All* comers' population vs Evorolimus-eluting stent) study.

Study limitations

This was a non-randomised observational study of relatively small patient population with the inherent limitations of such studies. Nevertheless, the findings were consistent with other studies using the same product and complications at 12 months were qualitatively similar to contemporary DES. The end points were not adjudicated by a core laboratory, but all events reported were verified by external, qualified clinical trial monitors. No ECG was performed as part of the 12-month FU and majority of the follow-up was via telephonic questionnaire raising the possibility of under-reporting of endpoints. However, the study endpoints were 'clinically driven' and every effort was made to capture clinical events by reviewing the patients' electronic health records in addition to the in person/telephonic follow-up.

CONCLUSIONS

The S-FLEX UK registry provides evidence that the S-SES can be used safely and effectively in routine clinical practice in UK patients with CAD being treated by PCI.




Figure 3 12-Month target lesion revascularisation and target lesion failure of contemporary stents.^{1–6} See references.^{10 22 37–40}

Author affiliations

- ¹Department of Cardiology, Cardiff and Vale University Health Board, Cardiff, UK
- ²Department of Cardiology, Royal Blackburn Hospital, Blackburn, UK
- ³Department of Cardiology, Raigmore Hospital, Inverness, UK
- ⁴Department of Cardiology, Royal Devon and Exeter Hospital, Exeter, UK
- ⁵Department of Cardiology, Salisbury District Hospital, Salisbury, UK
- ⁶Department of Cardiology and Institute of Cellular Medicine, Blackpool Victoria Hospital, Blackpool, UK
- ⁷Department of Cardiology, Eastbourne District General Hospital, Eastbourne, UK
- ⁸Department of Cardiology, The Heart and Lung Centre, Wolverhampton, UK
- ⁹Department of Cardiology, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, UK
- ¹⁰Freeman Hospital, Newcastle Upon Tyne, UK

Contributors The authors (Acho, SG, JS, AS, SNA, ACh, NP, BW, SC and AGZ) were principal investigators in their respective institutes and were involved in recruiting patients, authenticity of the data, dealing with queries and adjudicating any SAE. All authors (as mentioned above) were involved in drafting of the manuscript. ACho, SG and AGZ were responsible for the final version and overall content of the manuscript.

Funding This study was supported by SMT Pvt Ltd, Surat, India.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Local ethics committee/institutional review board (at each institution).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Sudipta Chattopadhyay <http://orcid.org/0000-0002-6421-6762>

REFERENCES

- 1 Colombo A, Drzewiecki J, Banning A, *et al.* Randomized study to assess the effectiveness of slow- and Moderate-Release polymer-based paclitaxel-eluting stents for coronary artery lesions. *Circulation* 2003;108:788–94.
- 2 Moses JW, Leon MB, Popma JJ, *et al.* Sirolimus-Eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med* 2003;349:1315–23.
- 3 Daemen J, Wenaweser P, Tsuchida K, *et al.* Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institution cohort study. *Lancet* 2007;369:667–78.
- 4 Kimura T, Morimoto T, Nakagawa Y, *et al.* j-Cypher registry Investigators. very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher registry. *Circulation* 2012;125:584–91.
- 5 Claessen BE, Beijk MA, Legrand V, *et al.* Two-Year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions. *Circulation* 2009;119:339–47.
- 6 Nakazawa G, Otsuka F, Nakano M, *et al.* The pathology of neoatherosclerosis in human coronary implants: bare-metal and drug-eluting stents. *J Am Coll Cardiol* 2011;57:1314–22.
- 7 Otsuka F, Vorpahl M, Nakano M, *et al.* Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. *Circulation* 2014;129:211–23.
- 8 Otsuka F, Yahagi K, Ladich E, *et al.* Hypersensitivity reaction in the US food and drug Administration-approved second-generation drug-eluting stents: histopathological assessment with ex vivo optical coherence tomography. *Circulation* 2015;131:322–4.
- 9 Otsuka F, Byrne RA, Yahagi K, *et al.* Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. *Eur Heart J* 2015;36:2147–59.
- 10 Kandzari DE, Mauri L, Koolen JJ, *et al.* Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. *Lancet* 2017;390:1843–52.
- 11 Joner M, Finn AV, Farb A, *et al.* Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. *J Am Coll Cardiol* 2006;48:193–202.
- 12 Hofma SH, van der Giessen WJ, van Dalen BM, *et al.* Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. *Eur Heart J* 2006;27:166–70.
- 13 Morton AC, Crossman D, Gunn J. The influence of physical stent parameters upon restenosis. *Pathol Biol* 2004;52:196–205.
- 14 Kollandaivelu K, Swaminathan R, Gibson WJ, *et al.* Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. *Circulation* 2011;123:1400–9.
- 15 Briguori C, Sarais C, Pagnotta P, *et al.* In-Stent restenosis in small coronary arteries: impact of strut thickness. *J Am Coll Cardiol* 2002;40:403–9.
- 16 Jabara R, Geva S, Ribeiro H, *et al.* A third generation ultra-thin strut cobalt chromium stent: histopathological evaluation in porcine coronary arteries. *EuroIntervention* 2009;5:619–26.
- 17 Chandwani P, Abhyankar AD, Prajapati JS, *et al.* Clinical performance of the Cobalt-Chromium biodegradable polymer coated sirolimus-eluting stent in an unselected real-world population. *Int J Clin Med* 2014;05:206–15.
- 18 BCIS. Update, 2016. Available: <https://www.bcis.org.uk/education/bcis-audit-report-adult-intervention-excl-tavi-calender-year>
- 19 Kandzari DE, Leon MB, Popma JJ, *et al.* Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease. *J Am Coll Cardiol* 2006;48:2440–7.
- 20 Stone GW, Midei M, Newman W, *et al.* Spirit III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. *JAMA* 2008;299:1903–13.
- 21 Leon MB, Mauri L, Popma JJ, *et al.* A randomized comparison of the endeavor zotarolimus-eluting stent versus the Taxus paclitaxel-eluting stent in de novo native coronary lesions. *J Am Coll Cardiol* 2010;55:543–54.
- 22 Stone GW, Rizvi A, Newman W, *et al.* Everolimus-Eluting versus paclitaxel-eluting stents in coronary artery disease. *N Engl J Med* 2010;362:1663–74.
- 23 Stefanini GG, Byrne RA, Serruys PW, *et al.* Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and leaders randomized trials. *Eur Heart J* 2012;33:1214–22.
- 24 Kang S-H, Park KW, Kang D-Y, *et al.* Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. *Eur Heart J* 2014;35:1147–58.
- 25 Palmaz JC, Bailey S, Marton D, *et al.* Influence of stent design and material composition on procedure outcome. *J Vasc Surg* 2002;36:1031–9.
- 26 Abhyankar AD, Prajapati J, Reddy S. Early vascular healing with biodegradable polymer coated sirolimus-eluting coronary stent implantation: assessed by optical coherence tomography results at 4-month follow-up. *Minerva Cardioangiologica* 2013;61:313–22.
- 27 Shetty R, Prajapati J, Pai U. Preliminary evaluation of clinical and angiographic outcomes with biodegradable polymer coated sirolimus-eluting stent in de novo coronary artery disease: results of the MANIPAL-FLEX study. *Hindawi Publishing Corporation Scientifica* 2016.
- 28 Pocock SJ, Lansky AJ, Mehran R, *et al.* Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. *J Am Coll Cardiol* 2008;51:23–32.
- 29 Serruys PW, Ong AT, Piek JJ, *et al.* A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the spirit first trial. *EuroIntervention* 2005;1:58–65.
- 30 Costa RA, Lansky AJ, Abizaid A, *et al.* Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions. *Am J Cardiol* 2006;98:443–6.
- 31 Meredith IT, Verheye S, Weissman NJ, *et al.* Six-Month IVUS and two-year clinical outcomes in the evolve FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. *EuroIntervention* 2013;9:308–15.
- 32 Lemos PA, Chandwani P, Saxena S, *et al.* Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the flex registry. *BMJ Open* 2016;6:e010028.

- 33 Finn AV, Joner M, Nakazawa G, *et al.* Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. *Circulation* 2007;115:2435–41.
- 34 Guagliumi G, Capodanno D, Ikejima H, *et al.* Impact of different stent alloys on human vascular response to everolimus-eluting stent: an optical coherence tomography study: the OCTEVEREST. *Catheter Cardiovasc Interv* 2013;81:510–8.
- 35 Gutiérrez-Chico JL, van Geuns RJ, Regar E, *et al.* Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE all Comers trial. *Eur Heart J* 2011;32:2454–63.
- 36 Gutiérrez-Chico JL, Gijzen F, Regar E, *et al.* Differences in neointimal thickness between the Abluminal and the Abluminal sides of Malapposed and side-branch Struts in a Polylactide Bioresorbable scaffold. *JACC Cardiovasc Interv* 2012;5:428–35.
- 37 Serruys PW, Silber S, Garg S, *et al.* Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. *N Engl J Med* 2010;363:136–46.
- 38 Fajadet J, Neumann F-J, Hildick-Smith D, *et al.* Twelve-month results of a prospective, multicentre trial to assess the everolimus-eluting coronary stent system (PROMUS element): the platinum plus all-comers randomised trial. *EuroIntervention* 2017;12:1595–604.
- 39 Kereiakes DJ, Meredith IT, Windecker S, *et al.* Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. *Circulation* 2015;8:e002372.
- 40 Pilgrim T, Heg D, Roffi M, *et al.* Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (bioscience): a randomised, single-blind, non-inferiority trial. *Lancet* 2014;384:2111–22.
- 41 Zaman A, de Winter RJ, Kogame N, *et al.* Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (talent): a prospective multicentre randomised controlled trial. *Lancet* 2019;393:987–97.